PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > Formulary Search > PAD Profile : Vigabatrin - Epilepsy
PAD Profile : Vigabatrin - Epilepsy
Brand Names Include :
Sabril, Kigabeq
Traffic Light Status
Status 1 of 2.
Status :
Blue
Important
Formulations :
- Sachets (powder)
- Tablets
Important Information :
Specialist initiation before transfer of prescribing to primary care
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Comments :
No comments returned.
Documents :
Status 2 of 2.
Guidelines
No guidelines returned.
Other Drugs
- Eslicarbazepine acetate
- Carbamazepine
- Clobazam
- Lacosamide
- Clonazepam
- Perampanel
- Ethosuximide
- Felbamate
- Rufinamide
- Gabapentin
- Stiripentol
- Lamotrigine
- Zonisamide
- Levetiracetam
- Oxcarbazepine
- Phenobarbital
- Piracetam
- Phenytoin
- Pregabalin
- Topiramate
- Sodium valproate
- Brivaracetam
- Sodium valproate
- Cannabidiol
- Cenobamate
- Primidone
- Tiagabine
Other Indications
No indications returned.
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
21 July 2020
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
Vigabatrin soluble tablets are currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission.
Associated BNF Codes
04. Central Nervous System
04.08.01. Control of epilepsy